If you are interested in speaking to this expert, contact the University’s Media & PR Team on
Kathleen has led Diabetes and Metabolism since November 2014, when she also became Chief Investigator of the Bart's Oxford (BOX) family study of type 1 diabetes. She is a molecular biologist interested in the mechanisms underlying autoimmunity. Her current projects include
- an international collaborative study of why some children develop type 1 diabetes in the first few years of life while others who have the markers of ongoing islet autoimmunity are not diagnosed until adulthood
- examining longitudinal genetic and islet autoantibody data from the BOX study to predict outcomes
- developing new biomarker assays
- understanding why children with Down's syndrome are at increased risk of autoimmunity
Current funding has been provided by Diabetes UK, the Juvenile Diabetes Research Foundation International and the European Foundation for the study of diabetes.
University of Bristol positions
Professor of Molecular MedicineBristol Medical School (THS)
Islet autoantibody profiles associated with higher diabetes risk in Lithuanian compared with English schoolchildren
Clinical and Experimental Immunology
- E-pub ahead of print
Multiple Sclerosis and Related Disorders
Slow progressors to type 1 diabetes lose islet autoantibodies over time, have few islet antigen-specific CD8+ T cells and exhibit a distinct CD95hi B cell phenotype.